More than 60% of patients with relapsed or refractory KMT2Ar acute leukemia responded to the menin inhibitor revumenib.

CURE partnered with SHARE Cancer Support to learn more about the importance of emotional well-being and a strong support ...

Cancer is complicated, especially with multiple diagnoses, oncologists, tests and integrative treatments, but AI can be a ...

Lazcluze demonstrated significant CNS activity, regardless of T790M status, in treating intracranial and leptomeningeal ...

Among patients with Merkel cell carcinoma, using ctDNA testing may help with watching the disease for potential recurrences ...

This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other ...

For patients with adenocarcinoma of the esophagus and esophagogastric junction, chemoradiotherapy and chemotherapy improved ...